IMAGING OF THYROID CANCER WITH RADIOLABELED OCTREOTIDE

该项目将测试标准诊断方法是否用于 新的临床环境将定位在其他方面难以捉摸的、分化良好的 受影响的患者中有40%或更多患有甲状腺癌。20名病人 将被研究；他们将：以前曾受到良好的对待- 分化型甲状腺癌，按常规无残留癌 除了他们的血清甲状腺球蛋白水平将会升高之外。 用核素显像仪对残存肿瘤进行评估 注射放射性药物111 in-奥曲肽后第二天。什么时候 有可能，成像方法将在甲状腺功能减退状态下重复进行 以查看此方法是否在查找 癌症。图像上的异常将被确认为肿瘤 超声、CT和/或活组织检查/切除。以前的组织学类型 将对已确诊的原发和转移肿瘤进行审查，以确定是否 这些图案将预测闪光照相结果。

This project will test whether a standard diagnostic method used in a new clinical setting will locate otherwise elusive, well-differentiated thyroid cancers in 40% or more of affected patients. Twenty patients will be studied; they will: have been previously treated for well- differentiated thyroid cancer, have no residual cancer by conventional tests except that their serum thyroglobulin levels will be elevated. They will be evaluated the residual tumors by scintigraphic imaging one day after injection of the radiopharmaceutical, 111-In-octreotide. When possible, the imaging method will be repeated in the hypothyroid state to see whether this approach provides more sensitivity in finding the cancers. Abnormalities on the images will be confirmed as tumors by ultrasound, CT and/or biopsy/excision. Histologic patterns of previously exicised primary and metastatic tumors will be reviewed to determine if the patterns will predict the scintigraphic results.